Medicilon IncMedicilon IncMedicilon IncMedicilon Inc
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact

Preclinical Safety Assessment and Drug Safety Testing

Home Featured Stories
NextPrevious

Preclinical Safety Assessment and Drug Safety Testing

By medicilon | Featured Stories | 7 September, 2016 |

The preclinical services that Medicilon offers focus on preclinical pharmacokinetic and drug safety assessment (evaluation) for foreign and domestic clients.

 

 Preclinical Safety Assessment

 

Preclinical Drug Safety Testing : In vitro and in vivo testing to determine if the drug is safe enough for human testing.

OUR SERVICES:

  • Single dose toxicity test (rodent and non-rodent)
  • Repeated dose toxicity study (rodent and non-rodent)
  • Safety pharmacology test: telemetry and non-telemetry to monitor the electrocardiogram and respiration of dogs and monkeys, rats FOB
  • Genotoxicity tests
  • Reproductive toxicity test
  • Immunogenicity test
  • Toxicokinetic
  • Partial toxicity test

Preclinical Safety Testing Requirements

  • Selection of the relevant animal species;
  • Age;
  • Physiological state;
  • Dose, route of administration, and treatment regimen; and Stability of the test material under the conditions of use.

Platform

  • The technical service platform of evaluation of biotech drug safety on non-human primate
  • The technical service platform of experiment on non-human primate
  • The technical service platform of drug discovery and screening based on protein crystallography
  • The technical service platform of evaluation of isotope labeling drug metabolism

The Projects

More than 30 packages of non-clinical drug safety evaluation and about 800 single toxicity studies have been completed since 2012. The tested articles include small molecular drugs, biotech drugs, vaccine (monovalent and multivalent ) and traditional Chinese medicine and natural drugs.

New Drug Application

Since 2012, 15 non-clinical safety evaluation packages and more than 60 single toxicity study data generated from MPR were used by the clients in IND application to CFDA, US FDA and Australia TGA separately.

New medicines or chemicals which may affect the health of humans are required by law to be tested on animals. These safety tests, which provide crucial information for planning human trials, represent a very small proportion of the development process for a new medicine. While animal tests cannot predict all of the reactions a human may have to a given substance, broader questions about effects on the heart, liver, lungs or skin are answered through animal studies so that its relative toxicity is known. Acute toxicity tests, where a single, high dose of a substance is given to animals, are performed early on in development. The results are used to design studies which examine the compound in more detail.

Safety testing begins early in the exploratory development of a potential drug, with acute toxicity tests. These are usually carried out on a rodent species, and a non-rodent mammalian species, as this gives the minimum data necessary for making comparisons between effects on different species.
Drug safety testing is a complicated process that involves many different steps to ensure the highest level of safety.

 

PRECLINICAL RESEARCH

The first step in developing and testing a new drug is preclinical research. Initially, scientists consult the vast amount of published information and databases to obtain as much background information as possible. If necessary, they perform studies to determine which germ, virus, chemical, or other factor causes a disease. Then the mechanisms of the disease are studied and new drugs are developed and evaluated for effectiveness and side effects using cell culture and whole animal models. Even though scientists minimize the number of animals used by testing drugs in cell culture whenever possible, it is still important to test drugs in animals.

PRECLINICAL SAFETY ASSESSMENT TESTING

Once a drug is shown to be effective in animals and to have a low incidence of side effects, it will be proceeded to safety assessment testing. These tests are conducted to evaluate drug safety in two different animal species, with animals receiving high doses of the new drug for 30 or 90 days. Animals are carefully monitored for side effects. After the study period, pathologists examine their organs for signs of drug toxicity. This drug safety testing in animals is carried out under guidelines mandated by law through the FDA. It is the last safety testing performed before the drug is given to people for clinical testing.

 

Contact us

Email : marketing@medicilon.com.cn

Tel : +86 021 5859 1500

Tips : Above is part of preclinical drug testing,Drug Safety Assessment. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

 

 

Relate News:

Drug Safety Evaluation

Medicilon’s Preclinical Toxicology Studies Services

Drug Safety Evaluation Center

Shanghai Drug Safety Evaluation Center

Acute toxicity test of chemical drugs

Non-clinical Safety Evaluation of Drugs

hERG Assay – Drug Preclinical Cardiac Safety Assessment

Acute toxicity test of chemical drugs

Drug safety assessment, Drug Safety Evaluation, Drug Safety Testing
NextPrevious

News

  • Medicilon Events
  • Media Coverage
  • Featured Stories

Tags

ADME (11) animal model (3) Animal Models (46) API (3) API process (3) BIAcore 8K (3) bioanalytical testing (3) Clinical Trails (2) consistency evaluation (3) COVID-19 (3) CRO (13) CRO company (8) CRO industry (6) diabetes treatment (3) Drug Discovery (7) drug safety cro (2) Drug Safety Evaluation (3) Elisa Assay (4) Formulation Research (3) GLP (3) green chemistry (3) IND (2) IND Application (3) IND Filing (5) IPO (3) LC-MS (4) Ligand Binding Assay (4) Medicilon Inc. (2) neurological disease (4) neurological diseases (4) neurological disorder (5) neurological disorders (4) PDX model (3) Peptide Drugs (3) Pharmacokinetics (7) pharmacokinetics research (6) pk study (2) Preclinical Research (6) PROTAC (4) Protein expression (4) Protein Purification (8) SAPA (5) Synthetic Biology (4) T cell (3) Western Blot Analysis (2)

Top Posts

  • 14 August, 2017

    Factors Affecting Pharmacokinetics of Drugs

  • 14 October, 2016

    Preclinical Drug Development Process

  • 14 February, 2017

    IND Enabling Studies FDA

Share

About Us

  • Medicilon Overview
  • Executive Team
  • CEO Message
  • Company History
  • Corporate Culture
  • Honor

Services

  • Chemistry
  • Biology
  • Bioanalytical
  • Drug Safety Evaluation
  • Formulation Development
  • Pharmacology
  • Pharmacokinetic
  • Integrated Projects

Customer Center

  • Customer Reviews
  • Download Center
  • Intellectual Property Protection
  • New Models of Collaboration

Contact Us

Shanghai Medicilon Inc.

Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China
Email: Marketing@medicilon.com
Website: www.medicilon.com

Copyright 2017 Shanghai Medicilon inc. | All Rights Reserved Privacy Policy
  • Languages
  • 中国日本대한민국
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact
Medicilon Inc